A Study of Ruxolitinib in Pancreatic Cancer Patients
Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This was to determine the efficacy, based upon overall survival, of ruxolitinib added to
capecitabine for the treatment of metastatic pancreatic cancer.